MUTATIONAL STATUS AND TREATMENT EFFICACY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA

I S Dyagil1, D A Bazyka1, I V Kirieieva1

  • 1State Institution «National Research Center for Radiation Medicine, Hematology and Oncology of the National Academy of Medical Sciences of Ukraine», 53 Yuriia Illienka St., Kyiv, 04050, Ukraine.

Summary

Resistance to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) is often caused by BCR::ABL1 gene mutations. Personalized therapy based on mutation status, utilizing newer TKIs like ponatinib and asciminib, is crucial for effective CML treatment.